2017-08344. Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc.  

  • Start Preamble

    ACTION:

    Notice of application.

    DATES:

    Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017.

    ADDRESSES:

    Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

    In accordance with 21 CFR 1301.33(a), this is notice that on December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

    Controlled substanceDrug codeSchedule
    Cathinone1235I
    Methcathinone1237I
    Mephedrone (4-Methyl-N-methylcathinone)1248I
    Aminorex1585I
    Alpha-ethyltryptamine7249I
    Lysergic acid diethylamide7315I
    Tetrahydrocannabinols7370I
    4-Bromo-2,5-dimethoxyamphetamine7391I
    4-Bromo-2,5-dimethoxyphenethylamine7392I
    4-Methyl-2,5-dimethoxyamphetamine7395I
    2,5-Dimethoxyamphetamine7396I
    3,4-Methylenedioxyamphetamine7400I
    N-Hydroxy-3,4-methylenedioxyamphetamine7402I
    3,4-Methylenedioxy-N-ethylamphetamine7404I
    3,4-Methylenedioxymethamphetamine7405I
    Dimethyltryptamine7435I
    Psilocybin7437I
    5-Methoxy-N,N-diisopropyltryptamine7439I
    1-[1-(2-Thienyl)cyclohexyl]piperidine7470I
    N-Benzylpiperazine7493I
    MDPV (3,4-Methylenedioxypyrovalerone)7535I
    Methylone (3,4-Methylenedioxy-N-methylcathinone)7540I
    Heroin9200I
    Normorphine9313I
    Norlevorphanol9634I
    Amphetamine1100II
    Methamphetamine1105II
    Nabilone7379II
    1-Phenylcyclohexylamine7460II
    Phencyclidine7471II
    Cocaine9041II
    Codeine9050II
    Ecgonine9180II
    Start Printed Page 19086
    Levomethorphan9210II
    Levorphanol9220II
    Meperidine9230II
    Metazocine9240II
    Methadone9250II
    Morphine9300II
    Thebaine9333II
    Levo-alphacetylmethadol9648II
    Remifentanil9739II
    Sufentanil9740II
    Carfentanil9743II
    Fentanyl9801II

    The company plans to manufacture reference standards.

    Start Signature

    Dated: April 18, 2017.

    Louis J. Milione,

    Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]

    BILLING CODE 4410-09-P

Document Information

Published:
04/25/2017
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2017-08344
Dates:
Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017.
Pages:
19085-19086 (2 pages)
Docket Numbers:
Docket No. DEA-392
PDF File:
2017-08344.pdf